Core Insights - The high cost of ECMO treatment is attributed to multiple factors including high equipment procurement costs, expensive consumables, operational and maintenance costs, and the impact of market supply and demand [1][2][3] - The average cost for ECMO treatment can exceed 200,000 yuan for two weeks, with daily expenses in the ICU exceeding 10,000 yuan [2][3] - The current market for ECMO in China is dominated by foreign brands, with significant reliance on imported equipment, which contributes to high treatment costs [2][4][6] Equipment and Technology - ECMO is a high-tech device used for severe heart and lung failure, providing external oxygenation and circulatory support [1][5] - The price of ECMO machines ranges from 1.5 million to 3.5 million yuan, with consumable costs averaging 50,000 to 70,000 yuan per use [2][3] - The technology and manufacturing processes for ECMO are complex, leading to high hardware costs and the need for specialized personnel for operation and maintenance [3][6] Market Dynamics - There is a significant disparity in ECMO availability between China and developed countries, with one ECMO machine available for every 2.8 million people in China compared to one for every 20,000 to 40,000 people in Germany [4] - The domestic ECMO market is beginning to see competition from local companies, with three firms receiving regulatory approval for their devices, marking a breakthrough in the industry [5][6] - Market share data indicates that as of 2024, major brands include Maquet, Shenzhen Hanno, and Jiangsu Saiteng, with Maquet holding the largest share at approximately 49.42% [6] Commercialization Challenges - The high costs associated with ECMO treatment have led to patient hesitance, creating barriers to wider adoption compared to developed nations [4][7] - The commercialization of domestic ECMO devices faces challenges including technology maturity, market education, and reimbursement approval [6][7] - Investment in the ECMO sector has decreased significantly since the peak during the COVID-19 pandemic, reflecting a more cautious approach from capital markets [6][7]